These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4163463)

  • 21. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2000; (2):3-5. PubMed ID: 11186726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of 17-alpha-norhydroxy-progesterone caproate (SH 582) in treatment of prostatic hypertrophy].
    Hara S; Suemitsu H; Matsuda G; Fukuhara I; Shiba T
    Hinyokika Kiyo; 1970 Sep; 16(9):501-7. PubMed ID: 4097362
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapy with progestational agents in advanced benign prostatic hypertrophy.
    Geller J; Angrist A; Nakao K; Newman H
    JAMA; 1969 Nov; 210(8):1421-7. PubMed ID: 4187537
    [No Abstract]   [Full Text] [Related]  

  • 24. [Mepartricin as medical treatment of benign prostatic hypertrophy].
    Micali F; Giurioli A; Virgili G; Vespasiani G
    J Urol (Paris); 1993; 99(6):293-5. PubMed ID: 7516370
    [No Abstract]   [Full Text] [Related]  

  • 25. [Assessment of voiding disorders and conservative pharmacological treatment of benign prostatic hypertrophy].
    Park YC; Takada M; Sugiyama T; Matsuura T; Kaneko S; Akiyama T; Kurita T; Yachiku S
    Hinyokika Kiyo; 1986 Nov; 32(11):1576-83. PubMed ID: 2435121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function.
    Kaplan SA
    Urology; 2004 Mar; 63(3):428-34. PubMed ID: 15028431
    [No Abstract]   [Full Text] [Related]  

  • 27. Saw palmetto extracts for benign prostatic hyperplasia.
    Segars LW
    J Fam Pract; 1999 Feb; 48(2):88-9. PubMed ID: 10037530
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of urination disorders with Raveron].
    Ichim V
    Z Urol Nephrol; 1970 Apr; 63(4):255-60. PubMed ID: 4109019
    [No Abstract]   [Full Text] [Related]  

  • 29. [Sabal serrulata extract in the management of symptoms of prostatic hypertrophy].
    Kondás J; Philipp V; Diószeghy G
    Orv Hetil; 1997 Feb; 138(7):419-21. PubMed ID: 9091843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Urodynamic evaluation of prostatic obstruction: practical aspect].
    Elhilali MM; Susset JG; Shoukry I
    Union Med Can; 1977 Nov; 106(11):1506-10. PubMed ID: 73249
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostatic enlargement.
    Blandy J
    Practitioner; 1989 Apr; 233(1466):512-7. PubMed ID: 2481304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Conservative treatment of benign prostatic hypertrophy--clinical effects of increased administration of Hachimijiogan and the relation between these effects and the "Sho" of Chinese medicine].
    Yachiku S; Kaneko S; Matsuura T; Akiyama T; Kurita T
    Hinyokika Kiyo; 1985 Mar; 31(3):545-51. PubMed ID: 2411117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction].
    Yamanaka N; Yamaguchi O; Kameoka H; Fukaya Y; Yokota T; Shiraiwa Y; Yokoyama J; Kumakawa K; Itou K; Kuma Y
    Hinyokika Kiyo; 1991 Dec; 37(12):1759-72. PubMed ID: 1723843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary flow rate in benign prostatic hypertrophy.
    Anikwe RM
    Int Surg; 1976 Feb; 61(2):109-11. PubMed ID: 56317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Conservative therapy of prostatic hyperplasia with urinary retention].
    Djulepa J
    Med Welt; 1983 Dec; 34(48):1377-9. PubMed ID: 6197601
    [No Abstract]   [Full Text] [Related]  

  • 36. [Tumorous prostatic diseases. I. Prostatic adenoma--genesis, clinical aspects, therapy].
    Reichelt H
    Z Allgemeinmed; 1974 May; 50(15):688-93. PubMed ID: 4137484
    [No Abstract]   [Full Text] [Related]  

  • 37. [On the use of a new drug in the therapy of prostatic adenoma: Tadenan. Clinical considerations on 23 cases].
    Durval A
    Minerva Urol; 1970; 22(3):106-11. PubMed ID: 4099512
    [No Abstract]   [Full Text] [Related]  

  • 38. [Uroflowmetry in the diagnosis of neurogenic bladder disorders].
    Schneider E
    Nervenarzt; 1975 Apr; 46(4):203-7. PubMed ID: 52127
    [No Abstract]   [Full Text] [Related]  

  • 39. When to investigate benign prostatic hyperplasia.
    Thomas D
    Practitioner; 1997 Jul; 241(1576):408-13. PubMed ID: 9425714
    [No Abstract]   [Full Text] [Related]  

  • 40. [Prostatilen effects on voiding disorders in patients with benign prostatic hyperplasia].
    Al'-Shukri SKh; Gorbachev AG; Borovets SIu; Belousov VIa; Kuz'min IV
    Urologiia; 2005; (5):25-6. PubMed ID: 16281835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.